KAIST is partnering with Thermo Fisher Scientific to establish SHARE Hub, a next-generation autonomous research hub where AI designs experiments and robots execute them. The initiative aims to accelerate scientific discovery and drug development by integrating researchers, AI systems, laboratory robotics, and experimental data into a self-driving research environment. KAIST (President Choongsik Bae) announced on August 27 that it had signed a memorandum of understanding with Thermo Fisher Sci
2026-08-27Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer platform that makes cancer cells send out their own danger signal—prompting immune cells to attack—while simultaneously delivering gene therapy. The approach is expected to offer a new treatment strategy that combines cancer immunotherapy and gene therapy in a single nanoparticle. Immunogenic cell death (ICD) is a process in which dying cancer cells send dange
2026-07-28A KAIST research team has developed a next-generation world model, an internal model an AI builds to understand and predict the world, that learns executable theories from observation alone. KAIST (President Choongsik Bae) announced on the 15th of July that a team led by Professor Sungjin Ahn from the School of Computing has proposed a new learning paradigm called Learning-to-Theorize (L2T), which trains AI to theorize how the world works using only observed information. The team also built t
2026-07-27Cells carry their own growth switches. When enough nutrients—amino acids in particular—are available, cells flip this switch on and begin to grow. Researchers at KAIST and Yonsei University have now uncovered the molecular mechanism by which amino acid signals activate this cellular growth switch. The findings are expected to open a new avenue for anticancer therapies that target abnormal growth signaling in tumor cells. KAIST (President Choongsik Bae) announced on July 26 that a
2026-07-27Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune “brakes” exploited by tumors to evade attack—show limited efficacy in some brain tumors. A KAIST research team found that B cell and antibody responses initiated in tumor-draining lymph nodes, rather than T cells alone, are critical to the antitumor effects of anti-CTLA-4 therapy, opening a new avenue for treating intractable brain tumors. KAIST (President
2026-07-20